As such, and in contradistinction to t-tau, enhanced CSF p-tau levels may differentiate AD from FTD [49, 50], Lewy body dementia [51], vascular dementia [52], PD [53], ALS, acute stroke [54], schizophrenia [55], and major depression [53]. The gene discussed is MAPT; the disease is frontotemporal dementia.